10-Q: Fulcrum Therapeutics Reports Q2 2025 Losses Amidst Losmapimod Discontinuation, Positive Pociredir SCD Data Emerges

Fulcrum Therapeutics experienced significant net losses in Q2 2025 following the termination of its Sanofi collaboration and discontinuation of the Losmapimod program, while reporting promising Phase 1b clinical data for its lead sickle cell disease candidate, Pociredir.

Summary

• Net loss for the six months ended June 30, 2025, was $34.95 million, a significant increase from a net income of $28.54 million in the same period of 2024, primarily due to the absence of the $80.0 million Sanofi upfront payment recognized in Q2 2024.
• Research and development expenses decreased by $10.64 million to $26.39 million for the six months ended June 30, 2025, mainly due to the suspension of the Losmapimod program and decreased headcount, partially offset by increased Pociredir development costs.
• General and administrative expenses decreased by $6.48 million to $13.83 million for the six months ended June 30, 2025, driven by reduced professional services and employee compensation costs.
• Cash, cash equivalents, and marketable securities totaled $214.1 million as of June 30, 2025, providing a projected cash runway into 2028.
• Topline data from the 12 mg dose cohort (n=16) of the Phase 1b trial of Pociredir in sickle cell disease showed a mean absolute fetal hemoglobin (HbF) increase of 8.6% (from 7.6% to 16.2%) at 12 weeks, with 7 of 16 patients achieving HbF levels greater than 20%.
• Pociredir treatment also led to an increase in F-cells from a mean of 34% to 67% and improvements in markers of hemolysis and erythropoiesis (decreased indirect bilirubin by 37%, decreased lactate dehydrogenase by 28%, decreased red cell distribution width by 27%, decreased reticulocyte counts by 30%).
• Mean hemoglobin concentration increased by 0.9 g/dL (from 7.8 g/dL to 8.7 g/dL) at 12 weeks with Pociredir treatment.
• Pociredir was generally well-tolerated in the 12 mg dose cohort, with no drug-related serious adverse events or discontinuations due to treatment-emergent adverse events; all treatment-related adverse events were Grade 1.
• The Losmapimod program for FSHD was discontinued following the Phase 3 REACH trial's failure to meet its primary endpoint in September 2024, leading to Sanofi's termination of the collaboration agreement effective April 17, 2025.
• The company achieved a $0.6 million preclinical milestone in April 2025 under the CAMP4 agreement for its Diamond-Blackfan Anemia (DBA) program.
• A workforce reduction from 80 to 51 full-time employees was implemented in September 2024 as part of a reprioritization strategy.
• As of June 30, 2025, the accumulated deficit reached $554.3 million.
• An at-the-market (ATM) offering program for up to $100.0 million in common stock was established in February 2024, but no shares have been sold under this program as of June 30, 2025.
• Pre-funded warrants for 8.5 million shares (RA Capital) and 0.85 million shares (another institutional stockholder) were issued in August 2024 in exchange for common stock, with 850,000 pre-funded warrants exercised as of June 30, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the Pociredir clinical data is very promising and the cash runway is extended, the significant net loss, the complete failure and discontinuation of the Losmapimod program, and the associated loss of the Sanofi collaboration revenue are major setbacks. The company is now heavily reliant on Pociredir's success and future financing.

Positives

• Pociredir's Phase 1b data for sickle cell disease showed promising results, including a mean 8.6% increase in absolute fetal hemoglobin (HbF) and 7 of 16 patients achieving HbF levels >20%, which is associated with a high reduction in vaso-occlusive crises.
• Pociredir demonstrated improvements in key markers of hemolysis and erythropoiesis, such as decreased indirect bilirubin (37%), lactate dehydrogenase (28%), red cell distribution width (27%), and reticulocyte counts (30%).
• Mean hemoglobin concentration increased by 0.9 g/dL with Pociredir treatment, indicating reduced red blood cell destruction and anemia.
• Pociredir exhibited a favorable safety profile, being generally well-tolerated with no drug-related serious adverse events or discontinuations due to treatment-emergent adverse events in the 12 mg dose cohort.
• The company's cash, cash equivalents, and marketable securities of $214.1 million as of June 30, 2025, are expected to fund operating expenses and capital expenditure requirements into 2028, providing a solid financial runway.
• A $0.6 million preclinical milestone was achieved in April 2025 under the CAMP4 agreement, advancing the Diamond-Blackfan Anemia (DBA) program.

Negatives

• The company incurred a significant net loss of $34.95 million for the six months ended June 30, 2025, a substantial decline from a net income of $28.54 million in the prior year period.
• The collaboration and license agreement with Sanofi for Losmapimod was terminated effective April 17, 2025, following the Phase 3 REACH trial's failure to meet its primary endpoint, resulting in no further milestone payments or royalties from this agreement.
• The Losmapimod program for FSHD was discontinued, representing a significant investment that did not yield a successful outcome.
• The company has an accumulated deficit of $554.3 million as of June 30, 2025, indicating a history of substantial losses.
• A workforce reduction from 80 to 51 full-time employees was implemented in September 2024, reflecting a strategic reprioritization and cost-cutting measure due to program setbacks.

Risks

• The company has incurred significant losses since inception and expects to continue incurring losses, potentially never achieving or maintaining profitability, with an accumulated deficit of $554.3 million as of June 30, 2025.
• Substantial additional funding will be needed, and inability to raise capital could force delays, reductions, or elimination of product development programs or commercialization efforts.
• The company is early in its development efforts with only one product candidate (Pociredir) in active clinical trials, and commercialization success is uncertain.
• Clinical drug development is lengthy, expensive, and uncertain, with preclinical and early clinical trial results not always predictive of future outcomes.
• Regulatory authorities may not consider the endpoints of clinical trials for rare diseases or new methodologies to predict or provide clinically meaningful results.
• Serious adverse events or unacceptable side effects identified during development, such as hematological malignancies observed in nonclinical toxicology studies for Pociredir, could lead to abandonment or limitation of product development.
• The company may not be successful in building a pipeline of product candidates or in-licensing additional candidates.
• Substantial competition exists from major pharmaceutical and biotechnology companies, including recently approved gene therapies for sickle cell disease.
• Reliance on contract manufacturing organizations (CMOs) and third parties for clinical trials poses risks of supply disruptions, quality issues, and failure to meet deadlines.
• Collaborations with third parties may not be successful, potentially limiting the market potential of product candidates.
• Inability to obtain, maintain, enforce, and protect patent protection for technology and product candidates could allow competitors to commercialize similar products.
• Failure to comply with obligations in intellectual property licenses and funding arrangements could lead to loss of intellectual property rights.
• Adverse developments in the financial services industry, such as bank failures, could affect funding access and financial condition.
• Global pandemics (e.g., COVID-19) and geopolitical events (e.g., Russia-Ukraine, Israel-Gaza, Iran conflicts) can impact clinical trials and supply chains.
• Changes in tax laws or their interpretation, such as the capitalization of research and development expenses and limitations on net operating loss carryforwards under Section 382, could adversely affect financial condition.
• Difficulty in enrolling patients in clinical trials, particularly for rare diseases or with stringent criteria, could delay or prevent regulatory approvals.
• FDA may not accept data from clinical trials conducted in foreign locations like Africa, requiring additional costly and time-consuming trials.
• Even if approved, product candidates may fail to achieve market acceptance due to efficacy, side effects, cost, or competition.
• Inability to establish sales, marketing, and distribution capabilities or secure third-party agreements could hinder commercialization.
• Market opportunities for rare diseases may be smaller than estimated, impacting revenue and profitability.
• Post-marketing restrictions or withdrawal from the market could occur if unanticipated problems arise with approved products.
• Compliance with complex and evolving global privacy and data security requirements could result in additional costs and liabilities.
• Recently enacted and future legislation, such as the Inflation Reduction Act of 2022 and executive orders on drug pricing, may increase the difficulty and cost of obtaining marketing approval and affect product pricing.
• Clinical trial and product liability lawsuits could divert resources and result in substantial liabilities.
• Internal computer and information technology systems, or those of third parties, are vulnerable to security compromises or breaches, potentially disrupting product development.
• Future success depends on retaining key executives and attracting qualified personnel, with recent executive transitions and workforce reductions posing challenges.
• Managing anticipated growth in development and potential commercialization capabilities may be difficult and costly.
• Executive officers, directors, and principal stockholders have significant control over company matters, potentially delaying or preventing changes in control.
• Provisions in corporate charter documents and Delaware law could make company acquisition more difficult.
• Stock price volatility and potential sales of a significant portion of outstanding shares could cause price declines.
• As a smaller reporting company, scaled disclosure requirements may make common stock less attractive to investors.
• Increased costs and management time are required for operating as a public company, including compliance with new regulations.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances Pociredir for sickle cell disease, continues preclinical studies, initiates additional clinical trials, and pursues discovery programs for inherited aplastic anemias like DBA. An IND submission for DBA is planned for Q4 2025. The company anticipates needing substantial additional funding beyond its current cash runway into 2028 to support ongoing and planned activities, including potential commercialization efforts. The 20 mg once daily dose cohort data for Pociredir is expected by the end of 2025.

Management Comments

• We expect our operating losses and negative operating cash flows to continue into the foreseeable future as we continue to advance and expand our research and development efforts.
• We expect to finance our future cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements.
• We expect that our cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these financial statements (into 2028).

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. Fulcrum Therapeutics' focus on genetically-defined rare diseases aligns with a growing trend in the industry towards precision medicine, which often targets smaller, underserved patient populations. The discontinuation of the Losmapimod program highlights the inherent high risk of late-stage clinical development, a common challenge in the sector. The promising early-stage data for Pociredir in sickle cell disease, a significant unmet medical need, positions the company in a competitive landscape that includes gene therapies, indicating a shift towards more advanced therapeutic modalities. The workforce reduction reflects a broader industry trend of strategic reprioritization and cost control in response to clinical setbacks and capital market conditions.

Comparison to Industry Standards

• The 8.6% mean absolute HbF increase for Pociredir in SCD patients is a positive indicator, especially with 7 of 16 patients achieving >20% HbF, which is associated with a 90% reduction in vaso-occlusive crises based on the company's real-world data analysis. This level of HbF induction is competitive with other HbF-inducing agents in development or approved for SCD, such as voxelotor (Oxbryta) which aims to increase HbF, though direct comparisons of absolute HbF increase percentages can vary based on trial design and patient population.
• The observed improvements in hemolysis and erythropoiesis markers (bilirubin, LDH, RDW, reticulocyte counts) with Pociredir are consistent with the desired mechanism of action for SCD therapies and are comparable to the effects seen with other effective treatments that reduce red blood cell destruction.
• The safety profile of Pociredir, with no drug-related serious adverse events and all treatment-related adverse events being Grade 1, appears favorable, especially when considering the safety concerns (e.g., hematological malignancies) associated with other EZH2/PRC2 inhibitors in the same class of drugs, such as tazemetostat (Tazverik) for epithelioid sarcoma and follicular lymphoma, which has a black box warning for secondary malignancies. This suggests a potentially differentiated safety profile for Pociredir within its class.
• The discontinuation of Losmapimod for FSHD after failing its Phase 3 primary endpoint is a common occurrence in drug development, similar to other companies that have faced late-stage clinical trial failures, such as Sarepta Therapeutics' golodirsen for Duchenne muscular dystrophy or Acadia Pharmaceuticals' pimavanserin for Parkinson's disease psychosis, which faced regulatory hurdles despite positive early data. This highlights the high-risk nature of biotech R&D.
• The company's cash runway into 2028 is relatively strong for a clinical-stage biotech, especially after a program discontinuation, providing more time for Pociredir's development compared to many peers who often have shorter runways (e.g., 12-18 months).

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• A securities action legal proceeding closed on March 28, 2025, with no related costs incurred during the three and six months ended June 30, 2025, other than attorneys' fees and defense costs.

Related Party Transactions

• In August 2024, the company entered into an exchange agreement with RA Capital Healthcare Fund, L.P. (RA Capital), a principal stockholder and related party, where RA Capital exchanged 8,500,000 shares of common stock for a pre-funded warrant to acquire 8,500,000 shares of common stock. No cash was exchanged in this transaction.

Stakeholder Impact

• Shareholders: Experienced dilution from pre-funded warrant exchanges and potential future equity offerings. The stock price is subject to volatility due to clinical trial outcomes and financial performance. The Losmapimod failure and Sanofi termination negatively impacted value, while positive Pociredir data offers future potential.
• Employees: A workforce reduction from 80 to 51 full-time employees occurred in September 2024, impacting those laid off and potentially affecting morale and retention for remaining staff.
• Customers (future): The discontinuation of Losmapimod means no product for FSHD patients from this company. The promising Pociredir data offers hope for sickle cell disease patients, but commercialization is still years away.
• Suppliers/Creditors: The company's extended cash runway into 2028 provides stability for ongoing operations and commitments, but the history of losses and need for future funding indicate continued reliance on external capital.

Next Steps

• Provide clinical data from the 20 mg once daily dose cohort of Pociredir by the end of 2025.
• Submit an Investigational New Drug (IND) application for the Diamond-Blackfan Anemia (DBA) program during the fourth quarter of 2025.
• Continue clinical development of Pociredir and ongoing preclinical studies.
• Advance clinical-stage product candidates into later stage trials.
• Pursue the discovery of drug targets for other genetically-defined rare diseases.
• Seek regulatory approvals for any product candidates that successfully complete clinical trials.
• Scale up manufacturing processes and capabilities or arrange for third-party manufacturing.
• Establish a sales, marketing, and distribution infrastructure for any approved products not out-licensed.
• Acquire or in-license additional products, product candidates, technologies, and/or data referencing rights.
• Maintain, expand, enforce, defend, and protect intellectual property.
• Hire additional clinical, quality control, scientific, operational, financial, and management personnel.

Key Dates

Recommendation

The company is at a critical juncture. The positive Phase 1b data for Pociredir in sickle cell disease is a significant de-risking event and provides a clear path forward for the lead program. The extended cash runway into 2028 is also a strong positive, giving the company ample time to advance Pociredir and the DBA program. However, the complete failure and discontinuation of the Losmapimod program, coupled with the loss of the Sanofi collaboration revenue, represents a major setback and highlights the inherent risks in biotech. The company has a substantial accumulated deficit and will require significant future capital. Given the early stage of Pociredir's development (Phase 1b) and the long road to commercialization, the stock remains highly speculative. A 'hold' recommendation reflects the balance between the promising clinical data and extended runway, offset by the recent program failure and ongoing financial challenges, suggesting investors should await further clinical milestones and clarity on future financing strategies before making a more definitive move.

Keywords

Sickle Cell Disease, Pociredir, Fetal Hemoglobin, HbF, Rare Diseases, Biopharmaceutical, Clinical Trials, Drug Development, Losmapimod, FSHD, Diamond-Blackfan Anemia, DBA, SEC Filing, 10-Q, Biotech, Clinical Hold, Cash Runway, Corporate Governance, Intellectual Property